News
NAUT
2.510
-4.20%
-0.110
Weekly Report: what happened at NAUT last week (0504-0508)?
Weekly Report · 5d ago
Most and least shorted small-to-mid-cap stocks
Seeking Alpha · 05/05 14:05
Most and least shorted healthcare stocks with up to $2B market cap in May
Seeking Alpha · 05/04 13:50
Weekly Report: what happened at NAUT last week (0427-0501)?
Weekly Report · 05/04 09:36
Guggenheim Remains a Buy on Nautilus Biotechnolgy (NAUT)
TipRanks · 04/29 11:39
Analysts Offer Insights on Healthcare Companies: Nautilus Biotechnolgy (NAUT) and Universal Health (UHS)
TipRanks · 04/28 22:00
Nautilus expects cash runway through 2027 while targeting oncology early access in H2 2026
Seeking Alpha · 04/28 21:02
Nautilus Q1 net loss narrows 12% to $14.7 million; R&D expense falls 16% to $9.7 million
PUBT · 04/28 20:31
Nautilus Biotechnology announces annual shareholder meeting webcast
PUBT · 04/28 20:17
Nautilus Reports Q1 Results, Advances Early Access And Platform Development; Stock Up
NASDAQ · 04/28 13:48
Nautilus Biotechnology Reports Q1 2026 Results: Full Earnings Call Transcript
Benzinga · 04/28 13:20
Nautilus Biotechnology Q1 net loss narrows as expenses fall
Reuters · 04/28 12:08
Nautilus Biotechnology GAAP EPS of -$0.12 beats by $0.02
Seeking Alpha · 04/28 12:05
*Nautilus Biotechnology Appoints Amber Faust Vice Pres of Global Sales >NAUT
Dow Jones · 04/28 12:01
*Nautilus Biotechnology 1Q Loss/Shr 12c >NAUT
Dow Jones · 04/28 12:01
BRIEF-Nautilus Biotechnology Q1 EPS USD -0.12
Reuters · 04/28 12:00
NAUTILUS BIOTECHNOLOGY REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
Reuters · 04/28 12:00
Press Release: Nautilus Biotechnology Reports First Quarter 2026 Financial Results
Dow Jones · 04/28 12:00
Press Release: Nautilus Biotechnology Reports -2-
Dow Jones · 04/28 12:00
Earnings Scheduled For April 28, 2026
Benzinga · 04/28 11:11
More
Webull provides a variety of real-time NAUT stock news. You can receive the latest news about Nautilus Biotechnology Inc through multiple platforms. This information may help you make smarter investment decisions.
About NAUT
Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprises the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs. Its platform consists of integrated reagents, fluidics, imaging, and ultra-dense nano-array flow cells.